Fujisawa Establishes US Research Institute
Fujisawa of Japan has established a new R&D company in the USA, the Fujisawa Research Institute of America. The new entity is the result of a reorganization of Fujisawa's US units, Fujisawa Laboratory and the Clinical Research Center, North America.
The new firm has two divisions, preclinical and clinical. The preclinical division is now located in the Northwestern University Evanston Research Park in Evanston. It was formerly located in Chicago at the Rush-Presbyterian St Luke's Medical Center. The clinical division has also been relocated from Philadelphia to Chicago.
Fujisawa says that the main purpose of the the new company is to expand the function of basic science while deepening scientific collaboration with the R&D division of Fujisawa Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze